AnaptysBio (ANAB) Could Be 49% Undervalued On Its Royalty Story

AnaptysBio (ANAB) has drawn fresh attention after recent trading left the stock down about 18% over the past month and roughly 30% over the past 3 months. That slump now frames how investors assess its royalty driven biotech model. Short term momentum for AnaptysBio has clearly cooled, with the share price down 18.4% over 30 days and 30.4% over 3 months. However, the 1 year total shareholder return of 118.2% and 3 year total shareholder return above 2.7x show a very different longer term...